Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017148889) HUMAN NEUTRALIZING ANTIBODIES BINDING TO INFLUENZA B NEURAMINIDASE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/148889 International Application No.: PCT/EP2017/054561
Publication Date: 08.09.2017 International Filing Date: 28.02.2017
IPC:
C07K 16/10 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08
against material from viruses
10
from RNA viruses
Applicants:
JANSSEN VACCINES & PREVENTION B.V. [NL/NL]; Archimedesweg 4 2333 CN Leiden, NL
Inventors:
BUJNY, Miriam, Verena; NL
VAN DER VLUGT, Remko; NL
DE MARCO, Donata; NL
Agent:
MANTEN, Annemieke; NL
VERHAGE, Richard, A; NL
BESLIER, Victor; NL
Priority Data:
16157974.301.03.2016EP
Title (EN) HUMAN NEUTRALIZING ANTIBODIES BINDING TO INFLUENZA B NEURAMINIDASE
(FR) ANTICORPS NEUTRALISANTS HUMAINS SE LIANT À LA NEURAMINIDASE DE LA GRIPPE B
Abstract:
(EN) The present invention provides influenza neuraminidase (NA)-binding human antibodies, which are capable of specifically binding to and neutralizing at least one influenza B virus strain from the B/Victoria lineage and/or at least one influenza B virus strain from the B/Yamagata lineage, as well as antigen-binding fragment thereof. The invention furthermore relates to the use of said antibodies or antigen- binding fragments in the diagnosis, prophylaxis and/or treatment of influenza infection.
(FR) La présente invention concerne des anticorps humains se liant à neuraminidase (NA) de la grippe, qui sont capables de se lier spécifiquement à et de neutraliser au moins une souche du virus de la grippe B de la lignée B/Victoria et/ou au moins une souche du virus de la grippe B de la lignée B/Yamagata, ainsi qu'un fragment de liaison à l'antigène correspondant. L'invention concerne en outre l'utilisation desdits anticorps ou fragments de liaison à l'antigène dans le diagnostic, la prophylaxie et/ou le traitement d'une infection grippale.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)